12 weeks of chemotherapy (stanford V) and involved field radiotherapy (RT) are highly effective for bulky and advanced stage Hodgkin's disease (HD): A limited institution ecog pilot study.

被引：0
|
作者：
Horning, SJ
Bennett, JM
Bartlett, NL
Williams, J
Neuberg, D
Cassileth, PA
机构：
来源：
BLOOD | 1996年 / 88卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：2681 / 2681
页数：1
相关论文
共 18 条
  • [1] 12-WEEKS OF CHEMOTHERAPY AND INVOLVED FIELD RADIOTHERAPY (RT) ARE HIGHLY EFFECTIVE FOR UNFAVORABLE HODGKINS-DISEASE (HD) - THE STANFORD V REGIMEN
    BARLETT, NL
    ROSENBERG, SA
    HOPPE, RT
    HORNING, SJ
    BLOOD, 1993, 82 (10) : A333 - A333
  • [2] Brief chemotherapy (Stanford V) and adjuvant radiotherapy for bulky or advanced Hodgkin's disease: An update
    Horning, SJ
    Rosenberg, SA
    Hoppe, RT
    ANNALS OF ONCOLOGY, 1996, 7 : 105 - 108
  • [3] Stanford V regimen plus consolidative radiotherapy is an effective therapeutic program for bulky or advanced-stage Hodgkin's disease
    Aversa, SML
    Salvagno, L
    Sorarù, M
    Mazzarotto, R
    Boso, C
    Gaion, F
    Chiarion-Sileni, V
    De Franchis, G
    Favaretto, AG
    Crivellari, G
    Banna, GL
    Sotti, G
    Monfardini, S
    ACTA HAEMATOLOGICA, 2004, 112 (03) : 141 - 147
  • [4] Very brief (8 week) chemotherapy (CT) and low dose (30 Gy) radiotherapy (RT) for limited stage Hodgkin's disease (HD): Preliminary results of the Stanford-Kaiser G4 study of Stanford V plus RT.
    Horning, SJ
    Hoppe, RT
    Breslin, S
    Baer, DM
    Mason, J
    Rosenberg, SA
    BLOOD, 1999, 94 (10) : 387A - 387A
  • [5] Assessment of the Stanford V regimen and consolidative radiotherapy for bulky and advanced Hodgkin's disease: Eastern Cooperative Oncology Group Pilot Study E1492
    Horning, SJ
    Wiliams, J
    Bartlett, NL
    Bennett, JM
    Hoppe, RT
    Neuberg, D
    Cassileth, P
    JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (05) : 972 - 980
  • [6] Involved field (IF) radiotherapy is as effective as extended field (EF) radiotherapy after 2 cycles of COPP/ABVD in patients (pts) with intermediate-stage Hodgkin's disease (HD): A randomized multicenter study.
    Engert, A
    Schiller, P
    Pfistner, B
    Herrmann, R
    Koch, P
    Bossevin, F
    Schaber, R
    Loeffler, M
    Duehmke, F
    Mueller-Hermelink, HK
    Paulus, U
    Rueffer, JU
    Sieber, M
    Wolf, J
    Diehl, V
    BLOOD, 2001, 98 (11) : 768A - 768A
  • [7] Efficacy of Abbreviated Stanford V Chemotherapy and Involved Field Radiotherapy in Early Stage Hodgkin's Disease: Mature Results of the G4 Trial.
    Advani, Ranjana H.
    Hoppe, Richard T.
    Baer, David M.
    Mason, Joseph
    Rosenberg, Saul A.
    Horning, Sandra J.
    BLOOD, 2009, 114 (22) : 666 - 667
  • [8] Assessment of favorable (F) versus unfavorable (U) early stage Hodgkin's disease (HD); the Stanford V plus radiotherapy (RT) experience.
    Advani, R
    Maeda, L
    Hoppe, RT
    Breslin, S
    Rosenberg, SA
    Baer, D
    Mason, J
    Horning, SJ
    BLOOD, 2005, 106 (11) : 548A - 548A
  • [9] Efficacy and late effects of Stanford V chemotherapy and radiotherapy in untreated Hodgkin's disease: Mature data in early and advanced stage patients.
    Horning, SJ
    Hoppe, RT
    Advani, R
    Warnke, R
    Baer, D
    Mason, J
    Rosenberg, SA
    BLOOD, 2004, 104 (11) : 92A - 92A
  • [10] EBVD combination chemotherapy plus low dose involved field radiation is a highly effective treatment modality for early stage Hodgkin's disease
    Angelopoulou, MK
    Vassilakopoulos, TP
    Siakantaris, MP
    Kontopidou, FN
    Boussiotis, VA
    Papavassiliou, C
    Kittas, C
    Pangalis, GA
    LEUKEMIA & LYMPHOMA, 2000, 37 (1-2) : 131 - 143
12